66.04
1.41 (2.18%)
| Previous Close | 64.63 |
| Open | 64.04 |
| Volume | 768,948 |
| Avg. Volume (3M) | 752,962 |
| Market Cap | 4,751,513,600 |
| Price / Sales | 120.55 |
| Price / Book | 4.89 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -336.77% |
| Diluted EPS (TTM) | -3.11 |
| Quarterly Revenue Growth (YOY) | 114.80% |
| Total Debt/Equity (MRQ) | 10.98% |
| Current Ratio (MRQ) | 8.49 |
| Operating Cash Flow (TTM) | -234.06 M |
| Levered Free Cash Flow (TTM) | -136.32 M |
| Return on Assets (TTM) | -19.47% |
| Return on Equity (TTM) | -32.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kymera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Guggenheim, 36.28%) | Buy |
| Median | 77.50 (17.35%) | |
| Low | 63.00 (Oppenheimer, -4.60%) | Buy |
| Average | 76.20 (15.39%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 58.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 26 Nov 2025 | 80.00 (21.14%) | Buy | 67.86 |
| 30 Sep 2025 | 68.00 (2.97%) | Buy | 56.60 | |
| Barclays | 05 Nov 2025 | 70.00 (6.00%) | Buy | 59.89 |
| 17 Sep 2025 | 60.00 (-9.15%) | Buy | 48.12 | |
| HC Wainwright & Co. | 05 Nov 2025 | 84.00 (27.20%) | Buy | 59.89 |
| 18 Sep 2025 | 70.00 (6.00%) | Buy | 51.16 | |
| Wells Fargo | 05 Nov 2025 | 69.00 (4.48%) | Buy | 59.89 |
| Guggenheim | 03 Nov 2025 | 90.00 (36.28%) | Buy | 59.72 |
| BTIG | 22 Oct 2025 | 75.00 (13.57%) | Buy | 55.80 |
| Mizuho | 21 Oct 2025 | 81.00 (22.65%) | Buy | 58.32 |
| Citigroup | 17 Oct 2025 | 80.00 (21.14%) | Buy | 59.83 |
| Oppenheimer | 01 Oct 2025 | 63.00 (-4.60%) | Buy | 54.66 |
| RBC Capital | 16 Sep 2025 | 70.00 (6.00%) | Buy | 48.78 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |